Results 131 to 140 of about 81,528 (247)

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang, Jingyun Li, Xian Li, Menglin Wang, Xiangli Yang, Li Shi, Zhiwei Cao, Yan Feng, Weiwei Liu, Zhendong Xu, Ruixia Ma, Xiaoping Gao, Wen Liu, Jinmei Xue, Xiaoyong Ren, Xuezhong Li, Xicheng Song, Yi Yang, Fang Quan, Lei Cheng, Weihong Jiang, Huabin Li, Jian Li, Huanhai Liu, Jianfeng Liu, Zheng Liu, Wei Lv, Qianhui Qiu, Xiangdong Wang, Yu Xu, Yuanteng Xu, Qintai Yang, Yucheng Yang, Jing Ye, Hongmeng Yu, Dongdong Zhu, Chengshuo Wang, Luo Zhang   +37 more
wiley   +1 more source

Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Spleen tyrosine kinase (SYK) has broad biological functions in inflammation and immunity. The orally administered SYK inhibitor BI 894416 was investigated in a single‐rising‐dose Phase I study in healthy volunteers and in a combined single‐ and multiple‐rising‐dose Phase Ib study in patients with mild asthma ...
Saskia Carstensen‐Aurèche, Tobias Litzenburger, Dorothy De Sousa, Reinhard Sailer, Ewald Benediktus, Denis Delic, Fabian Müller, Meike Müller, Jens M. Hohlfeld   +8 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Algorithms in Allergy: Hereditary Angioedema

Allergy, EarlyView.
Konrad Bork, Markus Magerl, Emel Aygören‐Pürsün, Henriette Farkas   +3 more
wiley   +1 more source

Early Detection of Lower Adherence to Long‐Term e‐Diary Recording: A Checkpoint to Target Early Educational Intervention in Seasonal Allergic Rhinitis?

Clinical &Experimental Allergy, EarlyView.
Adherence to e‐Diary reporting was investigated in a blended care setting among pollen allergic patients with heterogeneous cultural backgrounds. A stable ‘higher’ and a more variable ‘lower’ adherence cluster were identified. Early identification of lower adherence is possible and might inform early interventions to improve patient adherence. ABSTRACT
S. Dramburg, C. J. Hernandez Toro, U. Grittner, S. Tripodi, S. Arasi, A. Acar Şahin, X. Aggelidis, A. Barbalace, A. Bourgoin, B. Bregu, M. A. Brighetti, E. Caeiro, S. Caglayan Sozmen, L. Caminiti, D. Charpin, M. Couto, L. Delgado, A. Di Rienzo Businco, C. Dimier, M. V. Dimou, J. A. Fonseca, O. Goksel, D. Hernandez, T. M. Hoffmann, D. T. Jang, F. Kalpaklioglu, B. Lame, R. Llusar, M. Makris, A. Mazon, E. Mesonjesi, A. Nieto, A. Öztürk, L. Pahus, G. Pajno, I. Panasiti, N. G. Papadopoulos, E. Pellegrini, S. Pelosi, A. M. Pereira, M. Pereira, N. M. Pinar, E. Potapova, A. Priftanji, F. Psarros, C. Sackesen, I. Sfika, J. Suarez, M. Thibaudon, A. Travaglini, U. Uguz, V. Verdier, V. Villella, P. Xepapadaki, D. Yazici, P. M. Matricardi   +55 more
wiley   +1 more source

Dual dimensions of sensitization: age-stratified and disease-associated sIgE profiles in pediatric eczema and urticaria. [PDF]

Front Nutr
Yang L, Ni J, Zhu Z, Li C, Feng X, Chen N, Fang P, Yang J, Gao K.   +8 more
europepmc   +1 more source

ASCIA Guideline: Infant Feeding for Food Allergy Prevention

Clinical &Experimental Allergy, EarlyView.
The 2025 Australasian Society of Clinical Immunology and Allergy (ASCIA) Guideline: Infant Feeding for Food Allergy Prevention supersedes the 2016 ASCIA guideline. Key changes include specific recommendations about the timing of egg and peanut introduction to the infant's diet, alongside a recommendation regarding perioral rashes to support primary ...
S. L. Vale, M. J. Netting, C. J. Hornung, J. Smith, I. Roche, V. McWilliam, K. Hollinshead, C. South, A. Young, K. Rueter, K. P. Perrett, D. J. Palmer, P. Joshi, D. E. Campbell, J. J. Koplin, L. S. Ford   +15 more
wiley   +1 more source

Acute Urticaria as the Sole Manifestation of Dengue Fever: A Rare Case Report. [PDF]

Clin Case Rep
Goni MO, Biswas MS, Pk MMU, Khalil ME, Haque M, Siddika MA, Rahman MM.   +6 more
europepmc   +1 more source

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study

Clinical &Experimental Allergy, EarlyView.
Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan, Shengyang Yao, Lisha Li, Yongshi Yang, Wenchao Guan, Yin Wang, Xiaoshang Lou, Chuanhe Liu, Yanmin Bao, Shijie Zhuang, Li Sha, Ruonan Chai, Rongfei Zhu, Kai Guan   +13 more
wiley   +1 more source

Challenges in Differentiating Chronic Inducible Urticaria from Chronic Spontaneous Urticaria. [PDF]

J Inflamm Res
Bendayan E, Ton That A, Zhu CK, Netchiporouk E, Ben-Shoshan M.   +4 more
europepmc   +1 more source